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Abstract 
Introduction: GTPase regulator associated with focal adhesion kinase (GRAF) is a recently 
identified GTPase activating protein that has the tumor suppressor properties. However, the 
expression level of GRAF in leukemia had received less attention. The main purpose of this 
research was the evaluating of the expression level of GRAF in patients with acute myeloid 
leukemia (AML).  
Materials and methods: Ninety people participated in the research (45 patients with AML 
and 45 healthy persons). RNA was extracted from their blood samples and cDNA 
synthesized. The expression levels of GRAF mRNA were determined by QRT-PCR method. 
Results: The expression levels of GRAF mRNA were significantly lower in AML samples 
than the control groups. WBC count was high in down-regulated samples than up-regulated 
ones (P< 0.05). There was any significant difference between two groups in other laboratories 
parameters.  
Conclusion: In spite of rare studies on GRAF gene expression level in patients with AML, 
was shown that it's down-regulated in people with AML.  
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Introduction 
Acute myeloid leukemia (AML) is a 
heterogeneous disease with different 
pathogens in molecular levels (1-3). 
Cytogenetic findings are important as 
prognostic factor in patients with AML (4, 
5). Changes in some laboratory indices 
including WBC and platelet count, 
hemoglobin content has been seen in 
patients without chromosomal abnormality 
(6, 7). 
GRAF is a recently identified GTPase 
activating protein (8) that is a binding 
partner for FAK and has RhoA and dcdc42 
GAP activity in leukemic cells (8, 9). In 
addition, GRAF is able for specifically 
binding to PXXP motifs within the COOH 
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terminus of FAK and negatively modulate 
the small GTPase protein RhoA (10). 
Because the GRAF protein could bind to 
FAK and represent a negative regulator of 
Rho GTPases, FAK may modulate Rho 
activity by the recruitment and activation 
of GRAF (11). Some research has been 
shown that Rho GTPase activity was 
enhanced in some of human cancers (12). 
GRAF gene is highly homologous to other 
common GAP-encoding gene, BCR. 
Where it is involved in t (9; 22); BCR-
ABL1 translocation that typically observed 
in chronic myeloid and acute 
lymphoblastic leukemia's. Since that the 
GRAF is a negative regulator of Rho (13), 
the FAK/GRAF interaction could play a 
role in down-regulating Rho activity at 
adhesion sites (14). These evidences is 
show that GRAF has a major function on 
development cancers, however, GRAF 
expression rarely has studied in 
hematological malignancies. 
Focal Adhesion Kinase (FAK) is a critical 
mediator of integrin signaling pathway 
(15) and is involved in the regulation of 
survival and migration of the cell (16). 
Upon activation by integrins, FAK 
undergoes autophosphorylation on Tyr397 
(15, 17) and activate other signal 
transduction proteins, including 
Phosphotidil inositol 3 kinase (PI3K), c-
SRC, and GRAF (18). Using a monoclonal 
antibody against the C-terminal region of 
FAK could suppress of FAK and induced 
apoptosis and cell cycle arrest. Recently, 
inducible expression of FAK was 
demonstrated that positively regulate cell 
cycle progression (19). Aberrant 
expression of FAK observed in several 
malignant disorders like thyroid neoplasia, 
laryngeal and hepatocellular carcinoma, 
and hematological malignancy (20). 
Several mutations in genes involving in 
regulation of the signal transduction 
pathways has been mentioned in AML 
(21). Role of the several integrin 
molecules and their transduction signaling 
proteins like FAK in leukemia have been 
revealed (22-27). Nevertheless, GRAF 
gene expression alteration has received 
less attention in AML. The aim of the 
present study was to investigating on 
GRAF expression in patients with AML as 
prognostics markers.  
Materials and methods 
Patients: A total number of 45 AML 
patients and 45 healthy individuals as 
control group were included in the 
study.Following ethical committee 
approval, AML patients presenting to 
Molecular and Cytogenetic Laboratory of 
Ghaem Hospital, Mashhad University of 
Medical Scienses. Patients were recruited 
to the study after obtaining informed 
consent. Before any intervention a 5ml 
blood sample was obtained from healthy 
and patients. A diagnosis of leukaemia was 
confirmed based on French–American– 
British (FAB) classification and 
cytogenetic analysis. Other information 
including clinical, laboratory, and socio-
demographic data were extracted from 
laboratory and clinical history fills of 
patients.  
RNA extraction and cDNA synthesis: 
Mononuclear cells were isolated by Ficoll-
Hypaque gradient centrifugation 
immediately after sampling. Total cellular 
RNA was extracted from Mononuclear 
cells using the RNX plus™ kit according 
to the manufacturer’s recommendations 
(Cinnagen, Tehran, Iran) and was stored in 
-70ºC.The quantity and purity of RNA 
were confirmed by Thermo Scientific 
NanoDrop 2000 Spectrophotometer and 
agarose gel electrophoresis.  
cDNA synthesis were performed in a 
thermocycler (BIO RAD). One 
micrograms of total RNA was reverse 
transcribed to cDNA in a total reaction 
volume of 20 μl (containing dNTPs 1 mM 
each, random hexamers 0.5 μg), the 5x 
buffer supplied by the manufacturer and 
the deionized water (nuclease free) up to 
19 μl were added and the mixture was 
incubated at 37 ºC for 5 min period.  
Then 200 units of MMLV reverse 
transcriptase (FermentasInc) was added to 
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the reaction and were incubated for 60 min 
period and at 70 ºC for 10 min afterwards. 
Two negative control reactions, sterile 
H2O without RNA used as no-template 
control (NTC) and without MMuLV, 
accompanied each reaction, as well. 
RTQ-PCR for GRAF transcript 
expression: The mRNA expression levels 
of GRAF and beta 2-microglobolin (β2M) 
as a reference gene were quantified using 
real-time quantitative (qRT) polymerase 
chain reaction (PCR) analysis by SYBR® 
Green (TAKARA) method.  
These reactions were done in a 20 μl 
mixture containing 2 μl of synthesized 
cDNA with 10 μlTAKARA Pre mix, 6.6 μl 
deionized distilled sterile water, 0.5 μl of 
each primer, and 0.4 μlRox. The reaction 
mix was heated in a 7500 Real Time PCR 
thermocycler (Applied Biosystems, Foster 
City, CA, USA); initial denaturation at 95 
ºC for 10 min followed by 40 cycles of 95 
ºC for 40 sec, 60 ºC for 30 sec, 72 ºC for 
30 sec, and a final extension of 72 ºC for 5 
min. We were calculated the results from 
the QT-PCR         experiment through the 
2 
-ΔΔ Ct
 method to obtain expression of 
GRAF gene mRNA.      
For the detection of GRAF gene 
expression forward primer sequence: 
ATTCCAGCAGCAGCTTACA and the 
reverse primer sequence: 
GATGAGGTGGGCATAGGG were used, 
and for Beta-2 Microglobulin (β2M) 
primers were: 
CAGCAAGGACTGGTCTTTCTAT and 
GCGGCATCTTCAAACCTC. 
Statistical analysis 
Data were collected, analyzed, and 
reported as mean ± standard deviation. The 
Kolmogorov–Smirnov test applied to 
determine of data distribution. Chi-Square, 
Mann-Whitney test, and independent 
sample t-test were used to compare the 
differences between the groups. A p <0.05 
was considered as statistically significant. 
 
Results  
The general characteristics and clinical 
presentations of subjects have summarized 
in tables 1 and 2. There was no significant 
difference in the age of subjects. 
Cytogenetic study demonstrated the 
translocations (9; 22), (15; 17), (8; 21) and 
inversion (16) in patients with AML 
(Table 3). 
 
Table 1. Characteristics and clinical evaluation of 
the patients with acute myeloblastic leukemia and 
healthy individuals. 
Variables Patients Healthy 
Age (year) 43 (29-63) 44 (21-67) 
Male (n) 29 26 
Female (n) 16 19 
WBC (×109/L) 49.4 (1.8-233.9)* 6.7 (4-12.4) 
Hemoglobin (g/l) 79 (37-131) 124 (102-150) 
Platelet (×109/L) 62.6 (62-300) 200 (129-422) 
(* p < 0.05 vs. healthy group). 
 
Table 2. Clinical presentations of AMLs ' patients. 
Patients Variables 
%33.3 Splenomegaly 
%35.6 Fever 
%13.6 Hepatomegaly 
%11 Lymphadenopathy 
 
Table 3. Cytogenetic abnormalities of patients with 
AML. 
AML Parameters 
7 T (15; 17) 
2 T (8; 21) 
2 T (9; 22) 
1 In (16) 
(T and In represent translocation and inversion, 
respectively). 
 
Data of the present study showed that the 
expression of GRAF gene has significantly 
altered in patients with AML. In %84.4 of 
the patients, GRAF gene expression was 
down-regulated and up-regulated in %15.6 
(Figure 1). 
There was no significant difference in red 
blood cells and platelet count, 
hemoglobin's content between up and 
down-regulated groups (P > 0.05, data not 
shown)   
In patients with down-regulated of GRAF 
gene expression, WBC count was 
significantly higher than the up-regulated 
ones (p <0.05, Table 1). Concerning to 
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clinical characteristics, no significant 
differences were found between up- and 
down-regulated groups (P > 0.05). In 
addition, no differences were found 
between these two groups (P > 0.05) in 
cytogenetic abnormalities. Within AML 
patients, there was no difference in the 
expression of GRAF mRNA among 
different FAB subtypes (data not shown).
   
 
 
Figure 1. GRAF gene expression in AML and healthy subjects. The expression of GRAF gene was significantly 
down-regulated in patients with AML (¥ represent p value < 0.01 compared with healthy controls).  
Discussion 
The present study evaluated the GRAF 
gene expression in patients with acute 
myeloblastic leukemia. 
Data presented in this study demonstrated 
that alteration of GRAF transcript level in 
AML patients. So that was seen GRAF 
mRNA down-regulation in %84.4 of cases. 
Our results were in consistence to study 
conducted with Zhen Qian et al. (2010) 
inwhich that has shown a lower expression 
of GRAF transcript in myeloid 
malignancies. In contrast with this study 
Zhen Qian et al. did found any association 
between GRAF gene expression and WBC 
count (28). So that, in our study patients 
with a lower expression of GRAF had 
higher WBC count.  
Several mechanisms have been identified 
as cause of tumor suppressor down-
regulation in cancers. Among these, 
hypermethylation of promoter is one of 
important cause. In this regard, Bojesen 
and co-workers (2006) found that GRAF 
promoter was hypermethylated in 38% 
patients with AML. However, they did not 
study the GRAF level in primary leukemic 
cells of AML (29).  
The GRAF gene on 5q31chromosome has 
been identified as a translocation partner 
of MLL in a case of juvenile 
myelomonocytic leukemia (29). In 
addition, GRAF is known to be involved 
in RhoA regulation and is an essential 
component of the integrin signaling 
pathway (30). In attention to inhibitory 
effect of GRAF on the RhoA GTPase 
activity and function RhoA in the 
regulation of cell proliferation and 
transformation, likely GRAF is involved in 
the leukemogenesis in AML. 
The Rho family of GTPases is important 
proteins involve in regulating a different 
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physiological process such as cell growth, 
proliferation, and cell cycle progression 
(31). Rho GTPases are deregulated during 
malignant transformation and may be 
contributes to the invasiveness and 
metastasis of tumor cells (12, 32). Thus, 
GRAF acts as a negative regulator of 
integrin signaling transduction by the 
inhibitory effects on RhoA, and 
subsequent tumor suppressor activity. 
More studies are needed to clarify the 
relationship between RhoA, FAK, and 
GRAF in the context of development of 
leukemias and probably other tumors.  
In addition to cytogenetic abnormalities, 
WBC count is one of classical adverse 
prognostic factors in AML, as well. In 
attention to these finding, GRAF 
expressions may be correlated with the 
different characteristic of AML and it may 
be use as the independent prognostic 
markers for prediction of outcome in 
patients. For this purpose, more studies are 
need with long-term follow up and 
investigate of the association of GRAF 
expression with the patients' response to 
treatment and other prognostics factors. 
Conclusion 
Our study showed down-regulation of 
GRAF expression in relationship with 
enhancement of WBC count in patients 
with AML. Results of this study confirmed 
tumor suppressor effect of GRAF gene. It 
may be used from this finding as a new 
therapeutic approach in cancer therapy. 
Further research is suggested to 
determinate the importance of GRAF in 
immune response. 
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